医療用医薬品事業、並びに動物薬事業を展開する大手製薬企業。がん、糖尿病などの内分泌・代謝領域、ワクチン、関節リウマチなどの領域で事業を展開する。抗PD-1抗体のキイトルーダの適応拡大が、近年の売上を牽引している。近年の提携や買収では、2022年にAbSci社と提携。また、Orna Therapeutics社と提携し環状RNAモダリティの研究を開始している。また、2023年にPrometheus Biosceicnes社を買収し自己免疫疾患/消化器領域を強化している。
Rahway, New Jersey, United States
この企業の詳細情報の作成をご希望の方は、お気軽にリクエストください
設立 1668 年 | 推定従業員数 10001+ 名 | 累計調達額 $5.6M Ave：155.4M Med：22.5M | 提携企業数 366件 Ave：3.3 Med：1 | 論文数 0件 Ave： 13.2 Med： 4 | 特許数 0件 Ave： 13.2 Med： 4 |
パイプライン名 | 開発フェーズ | 対象疾患 | 標的分子/作用機序 | モダリティ | パートナー企業 |
|---|---|---|---|---|---|
MK-0482 | 探索 非臨床 P1 P2 P3 申請 上市 | Solid Tumors,Acute Myeloid Leukaemia (AML),Non-Small Cell Lung Cancer (NSCLC) | 不明 | 不明 | |
MK-0616 | 探索 非臨床 P1 P2 P3 申請 上市 | Hypercholesterolemia | Proprotein convertase inhibitors | 不明 | |
Nemtabrutinib (MK-1026) | 探索 非臨床 P1 P2 P3 申請 上市 | B-Cell Lymphoma,Richter Syndrome,Hematological Cancer | Agammaglobulinaemia tyrosine kinase inhibitors | 低分子化合物 | |
Quavonlimab (MK-1308) | 探索 非臨床 P1 P2 P3 申請 上市 | Malignant melanoma,Solid Tumors,Non-Small Cell Lung Cancer (NSCLC),Liver Cancer | Antibody-dependent cell cytotoxicity, Cytotoxic T-lymphocyte antigen 4 inhibitors, T lymphocyte stimulants | 抗体医薬 | |
quavonlimab + pembrolizumab (MK-1308A) | 探索 非臨床 P1 P2 P3 申請 上市 | Malignant melanoma,Solid Tumors,Small Cell Lung Cancer (SCLC),Renal Cell Carcinoma (RCC),ColoRectal Cancer (CRC),Liver Cancer | Antibody-dependent cell cytotoxicity, Cytotoxic T-lymphocyte antigen 4 inhibitors, Programmed cell death 1 receptor agonists, T lymphocyte stimulants | 抗体医薬 | |
MK-1942 | 探索 非臨床 P1 P2 P3 申請 上市 | Depression | 不明 | 不明 | |
MK-1942 | 探索 非臨床 P1 P2 P3 申請 上市 | Alzheimer's Disease | 不明 | 不明 | |
MK-2060 | 探索 非臨床 P1 P2 P3 申請 上市 | Thrombosis | Factor XI inhibitors | 抗体医薬 | |
Zilovertamab vedotin (MK-2140) | 探索 非臨床 P1 P2 P3 申請 上市 | Precursor B-cell lymphoblastic leukaemia-lymphoma,Solid Tumors,Chronic Lymphocytic Leukaemia (CLL),Mantle Cell Lymphoma (MCL),Diffuse Large B-cell Lymphoma (DLBCL),Ewing Sarcoma,Follicular Lymphoma (FL),Richter Syndrome | Apoptosis stimulants, Cell cycle inhibitors, Tubulin inhibitors, Tubulin polymerisation inhibitors | 抗体医薬 | |
KEYTRUDA (MK-3475) | 探索 非臨床 P1 P2 P3 申請 上市 | Hodgkin's Disease,Malignant melanoma,Cancer,Merkel cell carcinoma,Adenocarcinoma,Fallopian tube cancer,Gastrointestinal Cancer (GI Cancer),Mesothelioma,Peritoneal cancer,Bone cancer,Germ cell and embryonal neoplasms,Glioma,Leucoplakia,Lymphoma,Malignant fibrous histiocytoma,Malignant thymoma,Marginal zone B-cell lymphoma,Meningeal carcinomatosis,Meningioma,Osteosarcoma,Penile cancer,Sarcoma,Skin cancer,Soft Tissue Sarcoma,Leiomyosarcoma,Precursor cell lymphoblastic leukaemia-lymphoma,Gliosarcoma,Solid Tumors,Acute Myeloid Leukaemia (AML),Chronic Lymphocytic Leukaemia (CLL),Non-Small Cell Lung Cancer (NSCLC),Non-Hodgkin’s Lymphoma (NHL),Myelodysplastic Syndrome (MDS),Mantle Cell Lymphoma (MCL),Peripheral T-Cell Lymphoma (PTCL),Breast Cancer,Small Cell Lung Cancer (SCLC),Ovarian Cancer,Gastric Cancer,Pancreatic Cancer,Renal Cell Carcinoma (RCC),ColoRectal Cancer (CRC),Multiple Myeloma (MM),Brain Metastases,Cervical Cancer,Cholangio carcinoma,Cutaneous T-Cell Lymphoma (CTCL),Diffuse Large B-cell Lymphoma (DLBCL),Endometrial Cancer,Ewing Sarcoma,Follicular Lymphoma (FL),Glioblastoma (GBM),Head and Neck Cancer,Kaposi Sarcoma,Liver Cancer,Nasopharyngeal carcinoma (NPC),Neuroendocrine Tumors (NETs),Prostate Cancer,Rectal Cancer,Recurrent Respiratory Papillomatosis (RRP),Richter Syndrome,Squamous Cell Carcinoma (SCC),Thyroid Cancer,Uveal Melanoma,Adenoid Cystic Carcinoma (ACC),Hematological Cancer,Biliary Tract Cancer,Esophageal Cancer,Genitourinary Cancer,Urinary Bladder Cancer | Programmed cell death-1 receptor antagonists | 抗体医薬 | |
KEYTRUDA (MK-3475) | 探索 非臨床 P1 P2 P3 申請 上市 | Human papillomavirus infections | Programmed cell death-1 receptor antagonists | 抗体医薬 | |
MK-3655 | 探索 非臨床 P1 P2 P3 申請 上市 | Non-alcoholic fatty liver disease (NAFLD),Metabolic Dysfunction-associated Steatohepatitis (MASH/NASH) | KLB protein stimulants, Type 1 fibroblast growth factor receptor agonists | 抗体医薬 | |
MK-3655 | 探索 非臨床 P1 P2 P3 申請 上市 | Obesity | KLB protein stimulants, Type 1 fibroblast growth factor receptor agonists | 抗体医薬 | |
Favezelimab (MK-4280) | 探索 非臨床 P1 P2 P3 申請 上市 | Solid Tumors,Non-Small Cell Lung Cancer (NSCLC),Hematological Cancer | Antibody-dependent cell cytotoxicity, CD223 antigen inhibitors, T lymphocyte stimulants | 抗体医薬 | |
Favezelimab/pembrolizumab (MK-4280A) | 探索 非臨床 P1 P2 P3 申請 上市 | Solid Tumors,Small Cell Lung Cancer (SCLC),Renal Cell Carcinoma (RCC),ColoRectal Cancer (CRC),Esophageal Cancer | Antibody-dependent cell cytotoxicity, CD223 antigen inhibitors, Programmed cell death-1 receptor antagonists, T lymphocyte stimulants | 抗体医薬 | |
MK-4830 | 探索 非臨床 P1 P2 P3 申請 上市 | Malignant melanoma,Solid Tumors,Non-Small Cell Lung Cancer (NSCLC),Small Cell Lung Cancer (SCLC),Ovarian Cancer,Renal Cell Carcinoma (RCC),ColoRectal Cancer (CRC),Esophageal Cancer | Antibody-dependent cell cytotoxicity, LILRB2 protein inhibitors, T lymphocyte stimulants | 抗体医薬 | |
MK-5475 | 探索 非臨床 P1 P2 P3 申請 上市 | Pulmonary Hypertension (PH) | Guanylate cyclase stimulants | 不明 | |
Boserolimab (MK-5890) | 探索 非臨床 P1 P2 P3 申請 上市 | Solid Tumors,Non-Small Cell Lung Cancer (NSCLC),Small Cell Lung Cancer (SCLC) | Antibody-dependent cell cytotoxicity, CD27 antigen stimulants, T lymphocyte stimulants | 抗体医薬 | |
MK-2870 | 探索 非臨床 P1 P2 P3 申請 上市 | Solid Tumors,Non-Small Cell Lung Cancer (NSCLC),Breast Cancer | DNA topoisomerase I inhibitors | 抗体医薬 | |
MK-5684 | 探索 非臨床 P1 P2 P3 申請 上市 | Prostate Cancer | Cholesterol side chain cleavage enzyme inhibitors | 低分子化合物 | |
Efinopegdutide (MK-6024) | 探索 非臨床 P1 P2 P3 申請 上市 | Metabolic Dysfunction-associated Steatohepatitis (MASH/NASH) | Glucagon like peptide 1 receptor agonists, Glucagon receptor agonists | タンパク質 | |
Ladiratuzumab vedotin (MK-6440) | 探索 非臨床 P1 P2 P3 申請 上市 | Adenocarcinoma,Non-Small Cell Lung Cancer (NSCLC),Breast Cancer,Small Cell Lung Cancer (SCLC),Head and Neck Cancer,Prostate Cancer,Esophageal Cancer | Apoptosis stimulants, Mitosis inhibitors, Tubulin inhibitors, Tubulin polymerisation inhibitors | 抗体医薬 | |
Belzutifan (MK-6482) | 探索 非臨床 P1 P2 P3 申請 上市 | Von Hippel-Lindau disease | Endothelial PAS domain-containing protein 1 inhibitors | 低分子化合物 | |
Belzutifan (MK-6482) | 探索 非臨床 P1 P2 P3 申請 上市 | Solid Tumors,Pancreatic Cancer,Renal Cell Carcinoma (RCC),ColoRectal Cancer (CRC),Liver Cancer,Neuroendocrine Tumors (NETs),Biliary Tract Cancer | Endothelial PAS domain-containing protein 1 inhibitors | 低分子化合物 | |
Miransertib (MK-7075) | 探索 非臨床 P1 P2 P3 申請 上市 | Growth disorders,Proteus syndrome | Proto oncogene protein c-akt inhibitors | 低分子化合物 | |
TUKYSA (MK-7119) | 探索 非臨床 P1 P2 P3 申請 上市 | Gastrointestinal Cancer (GI Cancer),Gallbladder cancer,Solid Tumors,Non-Small Cell Lung Cancer (NSCLC),Breast Cancer,Gastric Cancer,ColoRectal Cancer (CRC),Cervical Cancer,Cholangio carcinoma,Endometrial Cancer,Biliary Tract Cancer,Urinary Bladder Cancer | ERBB 2 receptor antagonists, Phosphorylation inhibitors | 低分子化合物 | |
LYNPARZA (MK-7339) | 探索 非臨床 P1 P2 P3 申請 上市 | Fallopian tube cancer,Peritoneal cancer,Osteosarcoma,Solid Tumors,Non-Small Cell Lung Cancer (NSCLC),Breast Cancer,Small Cell Lung Cancer (SCLC),Ovarian Cancer,Gastric Cancer,Pancreatic Cancer,Renal Cell Carcinoma (RCC),ColoRectal Cancer (CRC),Cervical Cancer,Endometrial Cancer,Glioblastoma (GBM),Head and Neck Cancer,Prostate Cancer,Squamous Cell Carcinoma (SCC),Genitourinary Cancer,Urinary Bladder Cancer | Poly(ADP-ribose) polymerase inhibitors | 低分子化合物 | |
Vibostolimab (MK-7684) | 探索 非臨床 P1 P2 P3 申請 上市 | Malignant melanoma,Solid Tumors,Non-Small Cell Lung Cancer (NSCLC),Hematological Cancer | Antibody-dependent cell cytotoxicity, T lymphocyte stimulants, TIGIT protein inhibitors | 抗体医薬 | |
Pembrolizumab/vibostolimab (MK-7684A) | 探索 非臨床 P1 P2 P3 申請 上市 | Gallbladder cancer,Uterine cancer,Solid Tumors,Non-Small Cell Lung Cancer (NSCLC),Breast Cancer,Small Cell Lung Cancer (SCLC),ColoRectal Cancer (CRC),Endometrial Cancer,Head and Neck Cancer,Liver Cancer,Prostate Cancer,Hematological Cancer,Biliary Tract Cancer,Esophageal Cancer | Antibody-dependent cell cytotoxicity, Programmed cell death-1 receptor antagonists, T lymphocyte stimulants, TIGIT protein inhibitors | 抗体医薬 | |
LENVIMA (MK-7902) | 探索 非臨床 P1 P2 P3 申請 上市 | Malignant thymoma,Malignant melanoma,Osteosarcoma,Soft Tissue Sarcoma,Solid Tumors,Non-Small Cell Lung Cancer (NSCLC),Breast Cancer,Small Cell Lung Cancer (SCLC),Gastric Cancer,Renal Cell Carcinoma (RCC),ColoRectal Cancer (CRC),CNS Cancer,Endometrial Cancer,Glioblastoma (GBM),Head and Neck Cancer,Kaposi Sarcoma,Liver Cancer,Neuroendocrine Tumors (NETs),Prostate Cancer,Thyroid Cancer,Uveal Melanoma,Biliary Tract Cancer,Esophageal Cancer,Genitourinary Cancer | Platelet derived growth factor alpha receptor antagonists, Proto oncogene protein c ret inhibitors, Proto oncogene protein c-kit inhibitors, Type 1 fibroblast growth factor receptor antagonists, Type 3 fibroblast growth factor receptor antagonists, Type 4 fibroblast growth factor receptor antagonists, Type-2 fibroblast growth factor receptor antagonists, Vascular endothelial growth factor receptor 3 antagonists, Vascular endothelial growth factor receptor-1 antagonists, Vascular endothelial growth factor receptor-2 antagonists | 低分子化合物 | |
MK-8189 | 探索 非臨床 P1 P2 P3 申請 上市 | Schizophrenia | Phosphodiesterase 10A inhibitors | 不明 | |
MK-8189 | 探索 非臨床 P1 P2 P3 申請 上市 | Alzheimer's Disease | Phosphodiesterase 10A inhibitors | 不明 | |
Islatravir/MK 8507 (MK-8591B) | 探索 非臨床 P1 P2 P3 申請 上市 | HIV | Non-nucleoside reverse transcriptase inhibitors | 低分子化合物 | |
Islatravir (MK-8591D) | 探索 非臨床 P1 P2 P3 申請 上市 | HIV | Nucleoside reverse transcriptase inhibitors | 低分子化合物 | |
V184 | 探索 非臨床 P1 P2 P3 申請 上市 | Chikungunya virus infections | Immunostimulants | ワクチン | |
Gebasaxturev (V937) | 探索 非臨床 P1 P2 P3 申請 上市 | Malignant melanoma,Solid Tumors,Breast Cancer,Head and Neck Cancer,Squamous Cell Carcinoma (SCC) | CD55 antigen inhibitors, Cell death stimulants, Intercellular adhesion molecule 1 antagonists | 不明 | |
Clesrovimab (MK-1654) | 探索 非臨床 P1 P2 P3 申請 上市 | Respiratory syncytial virus (RSV) | Viral fusion protein inhibitors | 抗体医薬 | |
Molnupiravir (MK-4482) | 探索 非臨床 P1 P2 P3 申請 上市 | Eastern equine encephalomyelitis,Ebola virus infections,Middle East respiratory syndrome coronavirus,Venezuelan equine encephalomyelitis,COVID-19,Influenza,Respiratory syncytial virus (RSV) | Virus replication inhibitors | 低分子化合物 | |
Molnupiravir (MK-4482) | 探索 非臨床 P1 P2 P3 申請 上市 | Renal failure | Virus replication inhibitors | 低分子化合物 | |
Sotatercept (MK-7962) | 探索 非臨床 P1 P2 P3 申請 上市 | Vascular calcification,Pulmonary Hypertension (PH) | Activin inhibitors, Bone resorption factor inhibitors, Haemoglobin stimulants, Osteoblast stimulants, Osteoclast inhibitors, Osteogenesis stimulants, Transforming growth factor beta inhibitors | タンパク質 | |
Sotatercept (MK-7962) | 探索 非臨床 P1 P2 P3 申請 上市 | Diamond-Blackfan syndrome,Beta Thalassemia,Anemia | Activin inhibitors, Bone resorption factor inhibitors, Haemoglobin stimulants, Osteoblast stimulants, Osteoclast inhibitors, Osteogenesis stimulants, Transforming growth factor beta inhibitors | タンパク質 | |
Sotatercept (MK-7962) | 探索 非臨床 P1 P2 P3 申請 上市 | Myelofibrosis | Activin inhibitors, Bone resorption factor inhibitors, Haemoglobin stimulants, Osteoblast stimulants, Osteoclast inhibitors, Osteogenesis stimulants, Transforming growth factor beta inhibitors | タンパク質 | |
Sotatercept (MK-7962) | 探索 非臨床 P1 P2 P3 申請 上市 | Renal osteodystrophy | Activin inhibitors, Bone resorption factor inhibitors, Haemoglobin stimulants, Osteoblast stimulants, Osteoclast inhibitors, Osteogenesis stimulants, Transforming growth factor beta inhibitors | タンパク質 | |
Islatravir (MK-8591) | 探索 非臨床 P1 P2 P3 申請 上市 | HIV | Nucleoside reverse transcriptase inhibitors | 低分子化合物 | |
Doravirine/islatravir (MK-8591A) | 探索 非臨床 P1 P2 P3 申請 上市 | HIV | Non-nucleoside reverse transcriptase inhibitors, Nucleoside reverse transcriptase inhibitors | 低分子化合物 | |
V116 | 探索 非臨床 P1 P2 P3 申請 上市 | Pneumococcal infections | Immunostimulants | ワクチン | |
Vericiguat (MK-1242) | 探索 非臨床 P1 P2 P3 申請 上市 | Heart Failure | Guanylate cyclase stimulants | 低分子化合物 | Bayer |
Posaconazole (MK-5592) | 探索 非臨床 P1 P2 P3 申請 上市 | Candidiasis,Invasive bronchopulmonary aspergillosis,Mycoses,Oropharyngeal candidiasis,Chagas disease | 14-alpha demethylase inhibitors, Cytochrome P 450 enzyme system inhibitors | 低分子化合物 | |
Selumetinib (MK-5618) | 探索 非臨床 P1 P2 P3 申請 上市 | Glioma,Histiocytosis,Precursor cell lymphoblastic leukaemia-lymphoma,Solid Tumors,Non-Small Cell Lung Cancer (NSCLC),Non-Hodgkin’s Lymphoma (NHL),Gastric Cancer,ColoRectal Cancer (CRC),Kaposi Sarcoma,Neurofibromatosis Type 1,Neurofibromatosis Type 2,Uveal Melanoma,Biliary Tract Cancer | MAP kinase kinase 1 inhibitors, MAP kinase kinase 2 inhibitors | 低分子化合物 | AstraZeneca |
Gefapixant (MK-7264) | 探索 非臨床 P1 P2 P3 申請 上市 | Cough | Purinergic P2X3 receptor antagonists | 低分子化合物 | |
Cilastatin/imipenem/relebactam (MK-7655A) | 探索 非臨床 P1 P2 P3 申請 上市 | Intra-abdominal infections,Nosocomial pneumonia,Urinary tract infections,Bacteraemia,Bacterial infections,Sepsis,Gram negative infections,Ventilator-Associated Pneumonia (VAP) | Beta lactamase inhibitors, Cell wall inhibitors, Exopeptidase inhibitors | 低分子化合物 | |
Letermovir (MK-8228) | 探索 非臨床 P1 P2 P3 申請 上市 | Cytomegalovirus (CMV) Infection | Terminase inhibitors | 低分子化合物 | |
V-114 | 探索 非臨床 P1 P2 P3 申請 上市 | Pneumococcal infections | Immunostimulants | ワクチン | |
Fosaprepitant (MK-0517) | 探索 非臨床 P1 P2 P3 申請 上市 | Chemotherapy-induced nausea and vomiting | Neurokinin 1 receptor antagonists, Substance P inhibitors | 低分子化合物 | |
Doravirine (MK-1439) | 探索 非臨床 P1 P2 P3 申請 上市 | HIV | Non-nucleoside reverse transcriptase inhibitors | 低分子化合物 | |
Doravirine/lamivudine/tenofovir disoproxil fumarate (MK-1439A) | 探索 非臨床 P1 P2 P3 申請 上市 | HIV | Non-nucleoside reverse transcriptase inhibitors, Nucleoside reverse transcriptase inhibitors, Nucleotide reverse transcriptase inhibitors | 低分子化合物 | |
Daptomycin intravenous (MK-3009) | 探索 非臨床 P1 P2 P3 申請 上市 | Bacteraemia,Bacterial endocarditis,Staphylococcal infections,Gram Positive infections,Skin and Soft Tissue Infection (SSTI) | Cell wall inhibitors | ペプチド医薬 | |
Daptomycin intravenous (MK-3009) | 探索 非臨床 P1 P2 P3 申請 上市 | Osteomyelitis | Cell wall inhibitors | ペプチド医薬 | |
Sugammadex (MK-8616) | 探索 非臨床 P1 P2 P3 申請 上市 | Neuromuscular disorders | Binding agents | 低分子化合物 | |
Ertugliflozin (MK-8835) | 探索 非臨床 P1 P2 P3 申請 上市 | Type 2 Diabetes | Sodium-glucose transporter 2 inhibitors | 低分子化合物 | |
Human papillomavirus vaccine recombinant quadrivalent (V501) | 探索 非臨床 P1 P2 P3 申請 上市 | Anal Cancer,Anal intraepithelial neoplasia,Gynecologic Cancer,Penile cancer,Cervical Cancer,Condyloma acuminata | Immunostimulants | ワクチン | |
Human papillomavirus vaccine recombinant quadrivalent (V501) | 探索 非臨床 P1 P2 P3 申請 上市 | Human papillomavirus infections | Immunostimulants | ワクチン |
提携企業
提携企業 | 日付 | プレスリリース |
|---|---|---|
Amphista Therapeutics | 2025-07-16 | |
Antengene Corporation | 2025-05-20 | |
Redica Systems | 2025-05-15 | |
Cyprumed | 2025-04-16 | |
Jiangsu Hengrui Medicine | 2025-03-27 | |
IO Biotech | 2025-02-23 | |
Variational AI | 2025-02-20 | |
Eli Lilly,Purdue Pharma | 2025-02-19 | |
Epitopea | 2025-02-19 | |
Atropos Health | 2025-01-10 |
Merck & Co. (MSD) と似ている企業
免疫、がん、心疾患、内分泌、神経科学、ワクチンなどの領域で事業を展開する大手製薬企業。BioNTechとの提携によりCOVID-19 mRNAワクチンを販売し、2022年には370億ドルの売上を獲得。Pfizerの2022年の売上の最多を占める製品となっている。近年の買収や提携では、Trillium Therapeutics、Arena Pharmaceuticals、Biohaven Pharma、Global Blood Therapeutics、Seagen社などを立て続けに買収し、M&Aを活発化させている。また、近年の提携ではCytoReasonやGeroとの提携によるAI創薬/老化研究、CirCodeとの提携による環状RNA研究、Truveta社との提携による安全性RWD活用、大手VCのFlagship Pioneeringとの提携によるバイオテク設立前のインキュベーション技術へのアクセスなどを行っている。